XL 102
Alternative Names: AUR-102; XL 102Latest Information Update: 22 Feb 2024
At a glance
- Originator Aurigene Discovery Technologies
- Developer Aurigene Oncology; Exelixis
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase-activating kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Solid tumours
Most Recent Events
- 30 Nov 2023 Discontinued - Phase-I for Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO)
- 30 Nov 2023 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in USA (PO)
- 30 Nov 2023 Discontinued - Preclinical for Cancer (Combination therapy) in India (PO)